Adynxx Inc

ADYX NASDAQ
6.64
+0.33
+5.24%
Opening 13:30 05/24 EDT
Open
6.17
Prev Close
6.31
High
6.72
Low
6.17
Volume
5.24K
Avg Vol (3M)
149.33K
52 Week High
19.15
52 Week Low
5.67
% Turnover
0.63%
Market Cap
5.54M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Company Profile

Adynxx Inc., formerly Alliqua BioMedical, Inc., is a clinical stage biopharmaceutical company. The Company is focused on development of non-opioid therapeutics for the treatment of pain and inflammatory diseases. Its AYX platform utilizes a proprietary technology of non-opioid, disease-modifying transcription factor decoys. Its pipeline includes brivoligide and AYX2. Brivoligide product candidate is a potent and selective inhibitor of the transcription factor EGR1. Brivoligide is being developed for the prevention of post-surgical pain. AYX2 is a potent inhibitor of Kruppel-like Factors (KLF) six, nine and 15, transcription factors that maintain neuronal and glial activities involved in pain. AYX2 is being developed for the long-term suppression of chronic pain.
MORE >

Recently

Name
Price
%Change